Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission Control

Executive Summary: Mdivi-1 is a cell-permeable, selective inhibitor of the mitochondrial division dynamin-related GTPase 1 (DRP1) and Dnm1, mediating potent inhibition of mitochondrial fission and apoptosis in both yeast and mammalian cells (Li et al., 2025). At 50 μM in vitro, Mdivi-1 blocks DRP1 self-assembly, reduces mitochondrial fragmentation, and impedes Bax/Bak-dependent cytochrome c release—key to the intrinsic apoptosis pathway (ApexBio). In vivo, 50 mg/kg Mdivi-1 increases retinal ganglion cell (RGC) survival after ischemic injury in mice, decreasing GFAP expression without affecting blood pressure or behavior (ApexBio). Its unique selectivity enables advanced research in mitochondrial dynamics, apoptosis, and neuroprotection, with recommended use in DMSO-based workflows (Related Article). All claims are grounded in peer-reviewed and manufacturer data, ensuring high verifiability.

Biological Rationale

Mitochondrial fission is a tightly regulated process essential for organellar quality control, apoptosis, and cellular adaptation to stress. The dynamin-related protein 1 (DRP1) is a central GTPase orchestrating mitochondrial division by assembling at fission sites on the outer mitochondrial membrane (Li et al., 2025). Dysregulated DRP1 activity has been implicated in neurodegeneration, ischemic injury, and pulmonary hypertension (Li et al., 2025), making it a strategic target for mitochondrial dynamics research. Selective pharmacological inhibition of DRP1 with cell-permeable agents such as Mdivi-1 allows researchers to modulate mitochondrial morphology, dissect apoptotic signaling, and explore therapeutic avenues in models of disease (ApexBio).

Mechanism of Action of Mdivi-1

Mdivi-1 (SKU: A4472) is a small molecule that binds DRP1 and Dnm1, blocking their GTPase activity and oligomerization required for mitochondrial constriction (Dynamin-Inhibitory-Peptide.com). At 50 μM in vitro, Mdivi-1 inhibits DRP1 self-assembly and mitochondrial division, resulting in elongated, interconnected mitochondrial networks. Mechanistically, Mdivi-1 prevents Bid-activated Bax/Bak-dependent cytochrome c release, halting the intrinsic caspase-dependent and -independent apoptosis cascades (ApexBio). This selectivity enables precise perturbation of mitochondrial outer membrane permeabilization (MOMP), a pivotal checkpoint in cell fate decisions. Mdivi-1 does not directly affect other dynamin family GTPases and shows negligible activity in DRP1-null cell lines, underscoring its target specificity (Prostigmin.com).

Evidence & Benchmarks

• Mdivi-1 at 50 μM inhibits DRP1-mediated mitochondrial fission in yeast and mammalian cells, confirmed by fluorescence microscopy and biochemical assays (Li et al., 2025).
• In vitro, Mdivi-1 reduces annexin V staining and cytochrome c release, indicating decreased apoptosis in treated cells (ApexBio).
• In vivo administration of 50 mg/kg Mdivi-1 in C57BL/6 mice after ischemic retinal injury increases RGC survival and lowers GFAP protein expression without altering systemic blood pressure or behavior (ApexBio).
• Conditioned medium from ADAM10-overexpressing endothelial cells promotes SMC proliferation; this effect is reversed by Mdivi-1, confirming DRP1-dependence in vascular remodeling (Li et al., 2025).
• Mdivi-1 is insoluble in water/ethanol but dissolves at ≥17.65 mg/mL in DMSO, with optimal handling at 37 °C or via ultrasonic bath (ApexBio).

This article extends the mechanistic insights discussed in Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynam... by providing updated, quantitative in vivo benchmarks and clarifying solubility/handling recommendations for reproducible workflows.

Applications, Limits & Misconceptions

Mdivi-1 is widely applied in mitochondrial dynamics research, apoptosis assays, neuroprotection studies, and models of ischemic injury or neurodegeneration (ApexBio). Its specificity for DRP1 enables dissection of fission-dependent processes without broadly affecting the entire dynamin family. Researchers employ Mdivi-1 to study mitochondrial fragmentation, outer membrane permeabilization, and cell death pathways in both basic and translational frameworks. For further reading, Mdivi-1: Advancing Precision in Mitochondrial Fission and... details advanced strategies for neuroprotection and translational disease modeling, while this article provides updated evidence and workflow best practices.

Common Pitfalls or Misconceptions

• Non-specific effects at high concentrations: Mdivi-1 may inhibit other GTPases or display off-target mitochondrial effects at concentrations >100 μM (ApexBio).
• Water/ethanol solubility: Mdivi-1 is insoluble in water and ethanol; improper solvents can result in precipitation and experimental artifacts (ApexBio).
• Long-term solution storage: Solutions should not be stored long-term at room temperature; maintain at <-20 °C for optimal stability (ApexBio).
• Not effective in DRP1-null systems: Mdivi-1 requires DRP1 expression for activity; it is inactive in DRP1 knockout models (Prostigmin.com).
• Misinterpretation of apoptosis data: Mdivi-1 blocks intrinsic apoptosis but does not affect extrinsic (death receptor-mediated) pathways (Li et al., 2025).

Workflow Integration & Parameters

Mdivi-1 is typically reconstituted in DMSO to a stock concentration of up to 17.65 mg/mL. Warm to 37 °C or use an ultrasonic bath to fully dissolve the compound. Working dilutions should be prepared fresh in appropriate culture media, maintaining final DMSO concentrations below cytotoxic thresholds (commonly <0.1%) (ApexBio). Store solid Mdivi-1 at -20 °C; stock solutions are stable for several months at <-20 °C. For in vitro assays, concentrations of 25–50 μM are standard. In vivo, 50 mg/kg via intraperitoneal injection has demonstrated efficacy in murine models. For more on experimental integration, Mdivi-1 and the Future of Translational Mitochondrial Dyn... discusses advanced workflows and troubleshooting considerations; this article contributes updated handling and specificity guidance.

Conclusion & Outlook

Mdivi-1 (A4472) is a validated, selective DRP1 inhibitor that enables high-fidelity interrogation of mitochondrial fission, apoptosis, and neuroprotection in cell and animal models (Li et al., 2025). Its performance has been benchmarked across multiple systems with quantitative endpoints and robust negative controls. For detailed product specifications, protocols, and application notes, consult the Mdivi-1 product page. As mitochondrial dynamics remain at the forefront of disease modeling and therapeutic innovation, Mdivi-1 is poised to support next-generation discoveries in cellular physiology and translational science.